230968
Importance of Reproducibility in High-Throughput Biology: Predicting Sensitivity to Chemotherapy
Tuesday, November 9, 2010
: 5:30 PM - 5:50 PM
Keith Baggerly, PhD
,
Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX
Over the past few years, microarray experiments have supplied a lot of information about biological changes associated with various types of cancer. Many studies identify subgroups of patients with particularly agressive disease, so that we know who to treat. A corresponding question is how to treat them. Given the treatment options available today, this means trying to predict which chemotherapeutic regimens will be most effective. Several microarray studies have provided such predictions. Unfortunately, ambiguities associated with analyzing the data have made many of these results difficult to reproduce. In this talk, we will describe how we have analyzed the data, and reconstructed aspects of the analysis from the reported results. In some cases, these reconstructions reveal inadvertent flaws that affect the results. Most of these flaws are simple in nature, but their simplicity is obscured by a lack of documentation. These flaws have not, however, prevented clinical trials from being initiated.
Learning Areas:
Basic medical science applied in public health
Biostatistics, economics
Clinical medicine applied in public health
Conduct evaluation related to programs, research, and other areas of practice
Provision of health care to the public
Public health biology
Learning Objectives: 1. Discuss how microarray experiments provide information about biological changes associated with various types of cancer.
2. Describe how microarray techniques help to identify subgroups of patients with particularly agressive disease who need to be treated.
3. Demonstrate how to identify which treatment options may be most effective in treating such patients.
Keywords: Cancer, Statistics
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I am qualified to be an abstract author because I have more than 10 years of experience in the topic Reproducibility in High-Throughput Biology. I have presented similar talks in dozens of venues including NCI, the Joint Statistical Meetings, and various Universities.
Any relevant financial relationships? Yes
Name of Organization |
Clinical/Research Area |
Type of relationship |
Pfizer |
Biomarkers |
received talk honorarium |
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|